-
IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA
Ceftolozane-tazobactam is a new BL-BLI combination drug, and ceftolozane is a third-generation cephalosporin antibiotic, and tazobactam is a beta-lactamase inhibitor. At the recent 2023 IDWeek in the United States, Dr. Ryan K. Shields from the University of Pittsburgh presented a real-world observational study assessing the effectiveness of ceftolozane-tazobactam compared to ceftazidime-avibactam in treating multidrug-resistant Pseudomonas…
-
Can MRSA Surveillance Results Be Used to Discontinue Vancomycin for Infections Other Than Pneumonia?
At the IDWeek 2023, Dr. Rebekah W. Moehring from the Duke Center for Antimicrobial Stewardship and Infection Control at Duke University presented a fascinating report on the use of MRSA surveillance in guiding empirical therapy for MRSA and de-escalation strategies to optimize vancomycin antibiotic management.
-
Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases
Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy?…
-
IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection
Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and vancomycin-resistant Enterococcus (VRE), exhibit high resistance and rapid transmission. Previous studies have established a close relationship between intestinal CRE colonization and infection, but the relationship…
-
IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice
In a special session titled “Clinical Trials That May Change Your Practice” at the 2023 Infectious Diseases Week (IDWeek 2023), Dr. George R. Thompson III of University of California Davis Medical Center presented a fascinating report on “Clinical Trials in Fungal Diseases That May Change Your Practice”. He also granted an interview with “Infectious Disease…
-
Understanding and Advancing Cancer Control: Insights from Professor Dorothy Keefe, CEO of Cancer Australia
Professor Dorothy Keefe, the CEO of Cancer Australia, shares her insights in this exclusive interview. With decades of experience as a medical oncologist and a special interest in supportive care in cancer, Professor Keefe brings a wealth of knowledge to the discussion about cancer control and treatment.
-
Advancing Breast Cancer Control in the Philippines: Insights from Professor Corazon Ngelangel at the CCHIO Congress
Professor Corazon Ngelangel, a leading medical oncologist, recently shared her valuable insights at the CCHIO Congress. Her discussion provided a comprehensive overview of the progress in breast cancer control over the past 30 years. Professor Ngelangel’s expertise and experiences, particularly in the challenging times of the pandemic, underscored the significance of such international forums for…
-
Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress
Dr. Tony Ng, a renowned figure in the field of cancer research, recently participated in the 10-Day HIV-Related Congress. This event was a gathering of top minds in medicine, featuring doctors, scientists, and researchers from over 30 districts in China. Dr. Ng’s role as a speaker at this congress highlighted his significant contributions to cancer…
Connecting Medical Expertise through Media